陈白/文 2026年，科技将会如何改变我们的世界？ 具体答案目前可能并不清晰，但路径无疑是明确的，在AI互联网领域，新一年，更多的商业大战已经 箭在弦上。 高强度竞争迫使公司必须在极短时间内将前沿算力转化为易用的产品。科技公司积极参与竞争，也源于 它们对中国经济的笃定——只有相信未来的蛋糕足够大，才会愿意在当下投入如此高昂的竞争成本。 因此，竞争的喧嚣，其实是市场信心最坚实的注脚。每一次"开战"，都意味着大量研发预算转化为公共 技术资产，无数开发者和中小商家在激荡中找到新生态位，普通人的生活效率在无声中被提升。 我们不妨给科技公司的竞争以更多空间。甚至，在某种意义上，我们期待2026年能看到更多这样的"商 战"。因为只有充分竞争，昂贵的技术才会变廉价，小众的发明才会成为大众的工具。 2025年春节后，"外卖大战"卷土重来。而刚刚过去的春节，则上演了更激烈的"AI红包大战"。当数亿用 户通过生成式AI制作拜年视频、领取数字分身派发的红包时，AI技术完成了从实验室术语到国民级应 用的跨越。 尽管这些"大战"迅速普及了技术，但其模式本身始终伴随着争议。补贴烧钱、资源消耗、市场混战乃至 后期可能的垄断倾向，常被视为一 ...

Core Insights - Sprouts Farmers Market, Inc. (SFM) is a grocery store chain focusing on fresh, natural, and organic products, competing with major players like Whole Foods and Trader Joe's [1] - Goldman Sachs has set a price target of $111 for SFM, indicating a potential price increase of approximately 64.49% from its current price of $67.48 [1][5] Financial Performance - In Q4 2025, SFM reported an earnings per share (EPS) of 92 cents, exceeding the Zacks Consensus Estimate of 89 cents and improving from 79 cents in the same quarter the previous year [2][5] - Despite the positive EPS, net sales did not meet expectations but still grew by 8% year-over-year [2] Sales and Market Trends - SFM experienced a 1.6% increase in comparable-store sales and a significant 15% growth in e-commerce [3][5] - However, overall store traffic was slightly negative, and the company anticipates a challenging start to 2026, projecting a decline in comparable sales of 1-3% for Q1 2026 [3] Stock Performance - Currently, SFM's stock is priced at $67.48, with a market capitalization of approximately $6.57 billion [4] - The stock has seen a trading volume of 6,232,706 shares, with a low of $65.01 and a high of $69.32 on the day [4]

Core Viewpoint - Netflix is experiencing a decline in growth and profitability due to increased competition and market saturation, leading to margin compression and a challenging growth environment [2][4][12] Company Analysis - Netflix's growth expectations, built by Wall Street, are likely unsustainable given the current competitive landscape, including strong competitors like YouTube and HBO Max [2][3] - The company is facing a "law of large numbers" challenge, making it difficult to maintain previous growth rates [2][4] - Current stock performance shows a decline of approximately 43% from highs of about $134 since early July [7] Competitive Landscape - The streaming market is saturated with numerous high-quality options, limiting demand growth while supply continues to increase [10][12] - Netflix's strategy to redefine user monetization through app platform improvements and subscription pricing adjustments is seen as a positive move [13] Long-term Outlook - Despite short-term volatility and challenges, Netflix is considered a long-term investment opportunity due to its proven ability to navigate difficulties and innovate [6][16] - The company is viewed as one of the giants in the industry, alongside YouTube and Disney, with potential for recovery and growth in the future [16][18] Current Sentiment - The sentiment around Netflix is currently neutral, with the stock priced appropriately given the circumstances, and a need for improved viewer engagement to regain lost audience [19]

As filed with the Securities and Exchange Commission on December 22, 2025 Registration No. 333-290996 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Graphjet Technology (Exact name of registrant as specified in its charter) Cayman Islands 3620 N/A (State or other jurisdiction of incorporation or organization) (Primary standard industrial classification code number) (I.R.S. Employer Identification Num ...

Core Insights - Amicus Therapeutics (FOLD) shares reached a 52-week high of $11.14 on December 15, currently trading at $10.88, with a significant 87.6% increase over the past six months compared to the industry's 21% growth [1][4][9] Company Performance - The stock's rally is driven by investor optimism regarding Amicus' marketed products, particularly Galafold (migalastat) and the combination therapy Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), which are experiencing steady sales growth [2][20] - Galafold generated sales of $371.5 million in the first nine months of 2025, reflecting a 12% year-over-year increase, and is a key revenue driver for the company [7][9] - Pombiliti + Opfolda sales reached $77.5 million in the same period, marking a 61.5% year-over-year growth, indicating strong market uptake [9][13] Market Position and Competition - Amicus has successfully resolved patent litigation with Teva Pharmaceuticals, ensuring Galafold's market protection until January 2037, which is expected to safeguard sales from generic competition [10][11] - Despite the success of Galafold, the company's heavy reliance on this drug for revenue poses a risk, especially with increasing competition from established players like Sanofi and Takeda in the Fabry and Pompe disease markets [14][15][16] Valuation and Financial Estimates - Amicus is currently trading at a price-to-sales (P/S) ratio of 5.64, which is above the industry average of 2.46, but below its five-year mean of 8.99 [17] - The Zacks Consensus Estimate for 2025 earnings per share (EPS) has increased from 31 cents to 36 cents, while estimates for 2026 have decreased from 70 cents to 67 cents [18] Future Outlook - The company is expected to continue benefiting from strong sales of Galafold and incremental contributions from Pombiliti + Opfolda, indicating potential for growth [20] - Despite concerns regarding reliance on Galafold and competition, recent developments and improving earnings estimates suggest strong upside potential for Amicus [21][22]

Spurring real market competition is the best way for politicians to improve everyday life in Latin America, says @JPSpinetto (via @opinion) https://t.co/FSIgn0113w ...

Core Viewpoint - The proposed merger between Subsea 7 S.A. and Saipem SpA has raised significant concerns among Brazil's major oil operators regarding its potential impact on competition in the deepwater market, with the combined entity projected to have a backlog of €43 billion, annual revenues of around €21 billion, and over €2 billion in core earnings [1] Brazil's Industry Raises Concerns - Brazil's oil industry group IBP, representing major operators like Petrobras, ExxonMobil, and TotalEnergies, has formally warned antitrust regulator Cade that the merger could lead to increased project costs, slower execution, and pressure for exclusive long-term agreements [2] - Cade has requested additional data from the companies involved, indicating that crucial information was missing from initial filings, while Subsea 7 and Saipem have stated their cooperation with regulators [2] Competitive Pressure in SURF and Adjacent Markets - The strongest objections to the merger focus on the subsea umbilicals, risers, and flowlines (SURF) segment, where only a few global players operate, with TotalEnergies arguing that no remedy could fully mitigate the competitive risks posed by the merged entity [3] - The merged group would control eight of the twelve vessels worldwide capable of executing complex deepwater SURF work, raising concerns about market dominance [3][4] Cade's Deliberate Approach - Cade is taking a methodical approach, seeking input from local operators and coordinating with regulators in the U.S., U.K., and Mozambique, with Brazil being a critical battleground for the merger's approval [5] - Subsea 7's CEO has indicated that the merger is still expected to close in the second half of 2026, aligning with Cade's measured pace [5] Conclusion - Major operators like Petrobras, ExxonMobil, and TotalEnergies are warning that the merger could reshape pricing, timelines, and strategic control in the deepwater market, highlighting the need for regulators to balance efficiencies from scale against the preservation of competition [6] - The outcome of Cade's ruling will not only determine the fate of the Subsea 7-Saipem merger but also influence the broader direction of Brazil's offshore industry [6][7]

Report Industry Investment Rating - No information provided on the industry investment rating Core Viewpoints - Maintain buy on FAEACO 12.814 Perp due to its decent risk - return profile, larger cushion against the covenanted adj. net gearing ratio, and expected cash inflow from project deliveries in Australia and the UK [2] - Maintain buy on MEITUA 3.05 10/28/30 and MEITUA 0 04/27/28 (CB) as Meituan's overall credit profile remains robust with a strong net cash position, despite near - term headwinds [9] Summary by Related Catalogs Trading Desk Comments - Last Friday, there was small better buying on JP/AU financial names and TW lifers; balanced two - way flows on Chinese AMCs 2 - 5yr notes which closed 1 - 2bps tighter; MEITUAs were unchanged to 3bps wider [2] - In FRN space, PBs were buying Chinese banks, leasing, and SEA names, while AM flippers were taking profit; FAEACO 12.814 Perp dropped 5.6pts; LASUDE 26 increased 0.5pt; CWAHK 26 - 30 edged 0.1 - 0.5pt firmer [2] - In Chinese properties, VNKRLE 27 - 29 lowered 0.8 - 1.3pts; LNGFOR 29 was 1.7pts lower; ROADKG 28 edged 0.6 - 0.9pt higher; AMs were buying ZHHFGR and selling CPDEV [2] - Yankee AT1s were 0.1pt firmer, Japanese AT1s and insurance subs were largely stable, ACPM 5 1/8 Perp was 0.6pt higher; in SE Asia, some bonds were unchanged to 0.5pt higher [2] - This morning, BBLTB senior and JP financials tightened 1 - 2bps; VNKRLE 27 - 29 recovered 0.5 - 1.2pts; some bonds were 0.6 - 1.1pts higher, while others were 0.7 - 1.0pt lower [4] - MEITUAs were unchanged to 3bps wider post 3Q25 results announcement last Friday and unchanged this morning; IDASALs were unchanged this morning [4] Macro News Recap - Last Friday, S&P (+0.54%), Dow (+0.61%), and Nasdaq (+0.65%) were higher; UST yield was higher, with 2/5/10/30 year yield at 3.47%/3.59%/4.02%/4.67% [7] Desk Analyst Comments on Meituan - Meituan's 3Q25 adj. EBITDA dropped to negative RMB14.8bn due to the price war in China's food delivery market, with intense competition weighing on profitability [8] - The aggressive price war has eroded sector - wide margins, and the pressure is expected to persist until the competitive landscape becomes more rational, possibly through regulatory intervention [8] - Meituan's overall credit profile remains robust with a net cash position of RMB90.0bn as of Sep'25, which should cushion near - term earnings impact; near - term pressure on MEITUAs is expected, but further volatility presents better entry opportunities [9] Meituan's Financial Performance - Meituan's 3Q25 total revenue increased 2% yoy to RMB95.5bn, with core local commerce segment revenue decreasing 2.8% yoy to RMB67.4bn and turning into an operating loss of RMB14.1bn; new initiative segment revenue rose 15.9% yoy to RMB28.0bn, but segment loss increased 24.5% yoy to RMB1.3bn [12] - In 3Q25, selling and marketing expenses increased 90.1% yoy to RMB34.3bn, and R&D expenses increased 31.0% to RMB6.9bn; Meituan reported an operating loss of RMB19.7bn and negative adj. EBITDA of RMB14.8bn [13] - Meituan expects losses in the core local commerce segment and at the consolidated level to continue in 4Q25; the operating loss in the new initiative segment is expected to widen in 4Q25 for overseas expansion [13] - Meituan's liquidity position remained solid with a net cash position of RMB90.0bn as of Sep'25, down from RMB106.7bn as of Dec'24, and it had an average net cash position of RMB70.6bn in the past five years [14] Offshore Asia New Issues - No offshore Asia new issues were priced today [17] - Agricultural Bank of China Limited Tokyo Branch has a pipeline issue of 3 - year tenor with a coupon of SOFR + 100 and an issue rating of A1/-/- [18] News and Market Color - Last Friday, 70 credit bonds were issued onshore with an amount of RMB59bn; in Nov'25, 2,133 credit bonds were issued with a total amount of RMB2,286bn, a 17.8% yoy increase [22] - China Jinmao pledged a Shanghai property asset valued at RMB4.8bn as collateral for RMB9.9bn of syndicated loans [22] - China Water Affairs 1HFY26 EBITDA dropped 18.6% yoy to HKD2.2bn [22] - eHi Car 3Q25 fleet utilization rate rose 4.9 pct pt to 72.3% [22] - Seazen issued RMB616mn ABS backed by a Shanghai shopping mall [22] - HD Hyundai Heavy and its partner failed to win Poland's KRW8tn submarine project [22] - Mineral Industri Indonesia repurchased USD95.8mn of IDASAL 6.53 11/15/28 [22] - Melco Resorts Finance 9M25 operating revenue was up 14% yoy, and Studio City 9M25 operating revenue was up 10% yoy [22] - A Hong Kong tycoon seeks to sell some Rosewood Hotels [22] - Vedanta Resources is looking to raise USD600mn bank loan for refinance and secure INR20bn via INR - denominated NCDs at its subsidiary [22] - Vanke provided its entire stake in its property management arm as loan collateral to its controlling shareholder [22]

Core Insights - The animal health industry is facing challenges that require companies to innovate and adapt strategically [1] - Zoetis Inc. (NYSE:ZTS) is under scrutiny from KeyBanc Capital Markets regarding its product lineup and market positioning [2] - KeyBanc initiated coverage on Zoetis, highlighting ongoing challenges from its osteoarthritis (OA) pain monoclonal antibody (mAb) products and increased competition [3] Company Performance - Zoetis is experiencing headwinds from its OA pain mAb products, which have faced criticism on social media for potential side effects [4] - Despite these challenges, Zoetis is recognized for its history of innovation and is considered a high-quality company with revenue growth rates above the industry average and historically high profit margins [5] - The company reported third-quarter sales of $2.4 billion, reflecting a 1% year-over-year increase, slightly below the consensus estimate of $2.41 billion [6] Market Positioning - KeyBanc has assigned a Sector Weight rating to Zoetis until there is significant improvement in its OA pain mAb products or new high-revenue product launches [6] - Zoetis shares are currently trading at approximately 17.5x forward P/E, which is a discount compared to its two-year average of around 27x [6] - Growth in parasiticides, diagnostics, and dermatology portfolios was offset by a decline in mAb products for OA pain [7]

Summary of the Conference Call Transcript Industry Overview - The report focuses on the **China Consumer Appliances** industry, highlighting a significant decline in retail sales and market consolidation among leading brands [2][3][4]. Key Points and Arguments 1. **Retail Sales Decline**: - October omnichannel white goods retail sales fell by **29-36% YoY**, compared to a decline of **20-35% in September**. This decline is attributed to a high base in 2024 and fading domestic trade-in subsidies [2][3]. - The expectation is for continued double-digit YoY retail sales declines in November and December 2025 [2]. 2. **Market Share Dynamics**: - Industry leaders **Midea**, **Haier**, and **Gree** gained market share in October from tier-2 brands like **AUX** and **Hisense**, indicating ongoing industry consolidation during a downcycle [2][3]. - Midea and Haier increased their offline air conditioner (AC) value share by **1ppt** and **3ppt** YoY, respectively [3]. 3. **Price Trends**: - Offline average selling prices (ASPs) for ACs, washing machines (WMs), refrigerators, and range hoods fell by **12%**, **10%**, **12%**, and **5%** YoY, respectively. This decline is primarily due to a high base from trade-in subsidies in 2024 and increased competition [3][4]. 4. **Roborock's Performance**: - **Roborock** gained market share in robot vacuum cleaners (RVCs) and wet-dry vacuum cleaners despite an overall market decline. Its online sales for RVCs grew by **177% YoY**, while its market share increased by **21ppt** YoY to **30%** [4]. - Concerns were raised about Roborock's profitability due to high marketing investments and self-subsidies, which may negatively impact margins in Q4 2025 [4]. 5. **Small Kitchen Appliances**: - Online sales growth for small kitchen appliances decelerated to **5-10% YoY** in October 2025, with ASPs rising by **4-15% YoY** [5]. Additional Important Insights - The report indicates that the decline in retail sales is expected to persist, with industry leaders likely to continue gaining share due to brand segmentation strategies [3]. - The overall market for RVCs saw a **35% YoY** drop in online retail sales value in October, reflecting a high base from the previous year [4]. - The report emphasizes the importance of monitoring ASP trends and market share shifts as indicators of competitive dynamics within the consumer appliances sector [3][4]. Conclusion - The China Consumer Appliances industry is experiencing significant challenges with declining sales and price pressures, but leading brands are managing to consolidate their positions. Roborock's growth in a declining market highlights the potential for strategic investments to yield long-term benefits despite short-term profitability concerns.